Supplemental material
Journal of Medical Economics
Volume 25, 2022 - Issue 1
Nephrology
Quantifying the economic effects of ravulizumab versus eculizumab treatment in patients with atypical hemolytic uremic syndrome
Adrian R. Levya Department of Community Health and Epidemiology, Dalhousie University, Halifax, NS, CanadaCorrespondence[email protected]
https://orcid.org/0000-0002-8966-0966
https://orcid.org/0000-0002-8966-0966, Peter Chenb Alexion, AstraZeneca Rare Disease, Boston, MA, USAhttps://orcid.org/0000-0003-2015-9943
https://orcid.org/0000-0003-2015-9943, Karissa Johnstonc Broadstreet Health Economics and Outcomes Research, Vancouver, BC, Canadahttps://orcid.org/0000-0003-4570-9972
https://orcid.org/0000-0003-4570-9972, Yan Wangb Alexion, AstraZeneca Rare Disease, Boston, MA, USAhttps://orcid.org/0000-0001-9578-4781
https://orcid.org/0000-0001-9578-4781, Evan Popoffc Broadstreet Health Economics and Outcomes Research, Vancouver, BC, Canadahttps://orcid.org/0000-0002-3233-3147
https://orcid.org/0000-0002-3233-3147 & Ioannis Tomazosb Alexion, AstraZeneca Rare Disease, Boston, MA, USAhttps://orcid.org/0000-0003-0290-4583
https://orcid.org/0000-0003-0290-4583